Next week, our team is going to be dividing and conquering. Half of our team will travel to the Connected Health Conference in Boston and the other half is going up north to Creative Destruction Lab’s (CDL) first round of meetings in Toronto. CDL, hosted by our friendly neighbors up north, is a seed stage program. University of Toronto’s top MBA students are paired with startups to pitch to investors and venture capitalists. We will attend their machine learning and market for intelligence conference to showcase our product to over 700 attendees.
CDL chooses startups with deep science and technology innovations that can disrupt industries. CDL isn’t healthcare specific, yet it has multiple startups in the past that were part of the healthcare realm. Sensassure is a startup that detects urination events to alert nursing staff when changes are required. Cohesic improves cardiologist and radiologist physician documentation from free-form dictation. Other startups use artificial intelligence to detect skin conditions and map genetic interactions.
One of the unique aspects of this program is the wealth of scientists, ranging from experts in biodevices to leaders in image-guided therapy. As we are meeting with scientists, venture capitalists, and CDL’s partners next week, I imagine one of the questions we’ll be asked is, “How does Biovirtua disrupt healthcare?”. It’s a tough question, but one I’m confident that we can answer by highlighting the multiple interviews we had of physicians who talked about their difficulties in assessing patients with telehealth.
At BioVirtua, we are building a platform for facilitating telehealth and to connect care providers with remote patients. To know more, connect with us: email@example.com